These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 6126641)

  • 1. Cholinergic and dopaminergic mechanisms in Parkinson's disease after long term levodopa administration.
    Yahr MD; Clough CG; Bergmann KJ
    Lancet; 1982 Sep; 2(8300):709-10. PubMed ID: 6126641
    [No Abstract]   [Full Text] [Related]  

  • 2. Alleviation of severe emotional symptoms by carbidopa-levodopa, MSD, in a Parkinson's patient: a personal report.
    Doe J
    J Nerv Ment Dis; 1987 Mar; 175(3):185-6. PubMed ID: 3819716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parkinson's disease and motor fluctuations: long-acting carbidopa/levodopa (CR-4-Sinemet).
    Goetz CG; Tanner CM; Klawans HL; Shannon KM; Carroll VS
    Neurology; 1987 May; 37(5):875-8. PubMed ID: 3574696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Motor function in the normal aging population: treatment with levodopa.
    Newman RP; LeWitt PA; Jaffe M; Calne DB; Larsen TA
    Neurology; 1985 Apr; 35(4):571-3. PubMed ID: 3982646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paradoxial response to dopaminergic agents in parkinsonism.
    Wiener WJ; Kramer J; Nausieda PA; Klawans HL
    Arch Neurol; 1978 Jul; 35(7):453-5. PubMed ID: 666596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drugs for Parkinson's disease.
    Treat Guidel Med Lett; 2013 Nov; 11(135):101-6. PubMed ID: 24165688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal of sleep disturbance in Parkinson's disease by antiparkinsonian therapy: a preliminary study.
    Askenasy JJ; Yahr MD
    Neurology; 1985 Apr; 35(4):527-32. PubMed ID: 3982638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperthermia after discontinuance of levodopa and bromocriptine therapy: impaired dopamine receptors a possible cause.
    Figà-Talamanca L; Gualandi C; Di Meo L; Di Battista G; Neri G; Lo Russo F
    Neurology; 1985 Feb; 35(2):258-61. PubMed ID: 3969217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levodopa consumption reduces dopaminergic receptor responsiveness in Parkinson's disease.
    Vaamonde J; Luquin MR; Obeso JA
    Clin Neuropharmacol; 1989 Aug; 12(4):271-84. PubMed ID: 2804991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Parkinson's disease.
    Lieberman A
    Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):339-43. PubMed ID: 8507903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levodopa-carbidopa intestinal gel for treatment of advanced Parkinson's disease.
    Fernandez HH; Odin P
    Curr Med Res Opin; 2011 May; 27(5):907-19. PubMed ID: 21351823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutics of disordered movement.
    Sears ES
    Am Fam Physician; 1977 Sep; 16(3):145-54. PubMed ID: 143204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensorimotor disinhibition in Parkinson's disease: effects of levodopa.
    Caligiuri MP; Heindel WC; Lohr JB
    Ann Neurol; 1992 Jan; 31(1):53-8. PubMed ID: 1543350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter study of cabergoline, a long-acting dopamine receptor agonist, in Parkinson's disease patients with fluctuating responses to levodopa/carbidopa.
    Lieberman A; Imke S; Muenter M; Wheeler K; Ahlskog JE; Matsumoto JY; Maraganore DM; Wright KF; Schoenfelder J
    Neurology; 1993 Oct; 43(10):1981-4. PubMed ID: 8105422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Presynaptic neuron and postsynaptic dopamine receptor function in long term treatment of Parkinson's disease: a neuroendocrine study.
    Agnoli A; Ruggieri S; Baldassarre M; Rocco A; Del Roscio S; D'Urso R; Mearelli S; Falaschi P; Frajese G
    Prog Clin Biol Res; 1980; 39():215-24. PubMed ID: 6773067
    [No Abstract]   [Full Text] [Related]  

  • 16. Controlled-release levodopa/carbidopa. II. Sinemet CR4 treatment of response fluctuations in Parkinson's disease.
    Cedarbaum JM; Breck L; Kutt H; McDowell FH
    Neurology; 1987 Oct; 37(10):1607-12. PubMed ID: 3658164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolactin secretion in Parkinson disease.
    Eisler T; Thorner MO; MacLeod RM; Kaiser DL; Calne DB
    Neurology; 1981 Oct; 31(10):1356-9. PubMed ID: 6810204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.
    Colosimo C; Merello M; Hughes AJ; Sieradzan K; Lees AJ
    J Neurol Neurosurg Psychiatry; 1996 Jun; 60(6):634-7. PubMed ID: 8648329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parkinson's disease: therapeutic choices and timing decisions in patient management. Interview by Wayne Kuznar.
    Stacy M
    Geriatrics; 1999 Oct; 54(10):44-9; quiz 50. PubMed ID: 10542860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacotherapy: problems and practices.
    Muenter MD
    Clin Neuropharmacol; 1986; 9 Suppl 1():S23-36. PubMed ID: 3708606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.